Distinct Epigenetic Signatures Reveal How Aging and Type 2 Diabetes Differently Reshape Pancreatic Islets
核心洞察
A multiomics study of 144 pancreatic islet donors identified 996 age-associated and 902 diabetes-associated CpG sites with minimal overlap, revealing fundamentally distinct epigenetic programs.
Age-related methylation changes were enriched in gene promoter regions and linked to coordinated beta cell function, while diabetes-related changes clustered in enhancer regions suggesting stress-related alterations.
Researchers developed a blood-based methylation risk score that, combined with genetic risk data, achieved strong discriminatory performance for type 2 diabetes (搜索) classification (AUC: 0.91).
A landmark multiomics study published in Nature Communications has revealed that aging and type 2 diabetes (搜索) leave fundamentally different epigenetic footprints on pancreatic islets, challenging long-held assumptions about how these two processes intertwine. The findings offer new avenues for risk prediction and deepen understanding of islet dysfunction at the molecular level.
Researchers integrated DNA methylation, transcriptomic, and genotyping data from 144 pancreatic islet donors to disentangle how chronological aging and type 2 diabetes (搜索) independently influence epigenetic regulation. While advancing age remains the strongest known risk factor for type 2 diabetes, the biological mechanisms connecting the two have remained poorly understood — until now.
Two Distinct Epigenetic Landscapes Emerge
The analysis identified 996 age-associated cytosine phosphate guanine (CpG) sites and 902 diabetes-associated CpG sites across the genome. Strikingly, there was minimal overlap between the two groups, indicating that aging and diabetes operate through largely separate epigenetic programs within pancreatic islets.
Researchers also mapped 251 age-related and 310 diabetes-related CpG target genes, most of which were located at considerable genomic distances from their associated methylation sites — a finding that underscores the complexity of long-range epigenetic regulation.
Age-associated DNA methylation changes were predominantly found in gene promoter regions and formed coordinated gene modules linked to beta cell function, including insulin secretion. This suggests that aging drives an organized, programmed biological process within islets.
In contrast, diabetes-associated methylation changes were enriched in enhancer and non-regulatory regions, presenting a more heterogeneous pattern consistent with stress-related epigenetic alterations. The authors describe this as a "more variable" signature, reflecting the cellular stress and metabolic dysregulation characteristic of established disease.
Importantly, the observed relationships between CpG sites and target genes appeared independent of underlying genetic variation, indicating that these epigenetic mechanisms may exert effects beyond inherited genetic risk.
A Causal Link and a Predictive Tool
Further analysis using Mendelian randomization supported a potential causal role for age-associated DNA methylation changes in regulating KLHL42 (搜索), a genetic locus previously linked to type 2 diabetes (搜索) risk through genome-wide association studies. This finding strengthens the case that epigenetic aging changes are not merely correlative but may actively contribute to disease susceptibility.
The research team also developed a blood-based methylation risk score using age-associated CpG sites. This score correlated with insulin secretion and improved classification of type 2 diabetes (搜索) when combined with genetic risk information. The combined model achieved strong discriminatory performance, with an area under the curve (AUC) of 0.91 — a metric that places it among highly accurate predictive tools.
Implications for Future Diabetes Research and Care
The findings, led by Maurin L and colleagues, suggest that DNA methylation markers may offer valuable opportunities for identifying individuals at risk of diabetes well before clinical onset. By capturing the epigenetic signature of accelerated biological aging, such tools could complement traditional risk factors like family history, BMI, and glucose levels.
The study also reframes how researchers should think about the aging-diabetes connection. Rather than diabetes simply being a consequence of aging, the two processes appear to run on parallel but distinct epigenetic tracks — with aging driving coordinated beta cell changes and diabetes reflecting a more chaotic, stress-induced state.
As epigenetic clocks and methylation-based biomarkers continue to mature, future diabetes care may increasingly incorporate measures of biological aging alongside conventional metabolic parameters. The blood-based risk score developed in this study represents an early step toward that vision, though further validation in larger, diverse populations will be essential before clinical translation.